CD19 Mouse Monoclonal Antibody (PE conjugated) [Clone ID: OTI3B10]

CAT#: TA506236HM

CD19 mouse monoclonal antibody,clone 3B10, PE conjugated

Conjugation: Unconjugated Biotin DyLight 488 HRP PE



  View other "OTI3B10" antibodies (6)

Need it in bulk or conjugated?
Get a free quote

CNY 6,160.00


货期*
现货

规格
    • 100 ul

经常一起买 (3)
beta Actin Mouse Monoclonal Antibody, Clone OTI1, Loading Control
    • 30 ul

CNY 300.00
CNY 1,430.00


Recombinant protein of human CD19 molecule (CD19), 20 µg
    • 20 ug

CNY 2,900.00


Transient overexpression lysate of CD19 molecule (CD19)
    • 100 ug

CNY 3,080.00

Specifications

Product Data
Clone Name OTI3B10
Applications FC, IF, IHC, WB
Recommend Dilution WB 1:4000, IHC 1:150, IF 1:100
Reactivity Human
Host Mouse
Clonality Monoclonal
Immunogen Full length human recombinant protein of human CD19(NP_001761) produced in HEK293T cell.
Concentration 0.5 mg/ml
Purification Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G)
Conjugation PE
Storage Condition Store at +4°C.
Predicted Protein Size 60.9 kDa
Gene Name CD19 molecule
Background Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. This gene encodes a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. [provided by RefSeq, Jul 2008]
Synonyms B4; CVID3
Reference Data
Protein Families Druggable Genome, Transmembrane
Protein Pathways B cell receptor signaling pathway, Hematopoietic cell lineage, Primary immunodeficiency
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Other Versions

Customer Reviews 
Loading...